Mesoblast (ASX: MSB) — Stock Profile

Mesoblast Limited is an Australian regenerative medicine company operating across Australia, the United States, Singapore, and Switzerland, focused on developing cell-based therapies for serious inflammatory, cardiovascular, and musculoskeletal conditions. Its proprietary technology platform is built on mesenchymal lineage cells, a specialized cell type that underpins its entire product pipeline and distinguishes its approach from conventional pharmaceutical development.

The company's lead candidate, Remestemcel-L, is in Phase III clinical trials for steroid refractory acute graft versus host disease, biologic refractory inflammatory bowel disease encompassing ulcerative colitis and Crohn's disease, chronic heart failure, and chronic low back pain due to degenerative disc disease. Mesoblast is also advancing MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. Strategic partnerships with Tasly Pharmaceutical Group, JCR Pharmaceuticals, and Grünenthal support the development and commercialization of additional candidates including MPC-150-IM, MPC-25-IC, and Ryoncil across indications ranging from pediatric graft versus host disease to wound healing and neonatal brain injury. Incorporated in 2004, the company is headquartered in Melbourne, Australia.